GE BioPharma sale to Danaher is complete

By The Science Advisory Board staff writers

The divestment of GE's BioPharma business unit to Danaher is complete, according to an announcement by both companies on March 31.

As part of Danaher, the business will be called Cytiva and will operate as a standalone company within Danaher's Life Sciences segment.

The deal, which was originally announced in February 2019, was completed with a cash consideration of around $20 billion to GE as well as Danaher's assumption of certain pension liabilities.


Copyright © 2020 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?